Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
norUrsodeoxycholic acid in Primary Sclerosing Cholangitis
NCT03872921Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Feb 2018
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing norUrsodeoxycholic acid with Placebo (2 arms). Primary endpoint: Partial normalization of serum Alkaline Phosphatase (s-ALP) and no worsening of disease stage (Ludwig classification) at 2 years. Started Feb 2018; status: active, not recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03872921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872921.